Related Experiment Videos
Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent
S Novo1, M G Abrignani, G Pavone
1Division of Cardiology, Hospital of Trapani, Italy.
Insights
Captopril and Ticlopidine combination therapy significantly improves blood pressure and walking distance in hypertensive patients with peripheral obstructive arterial disease. Chronic treatment enhances these benefits for intermittent claudication management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension and peripheral obstructive arterial disease (POAD) often coexist.
- Intermittent claudication is a common symptom of POAD, impacting quality of life.
Purpose of the Study:
- To evaluate the efficacy of Captopril (C) and Ticlopidine (T) alone and in combination for hypertensive patients with POAD.
- To assess the long-term effects of combined therapy on blood pressure and walking parameters.
Main Methods:
- Randomized trial with 24 male hypertensive patients with POAD.
- Sequential administration of Captopril, Ticlopidine, their combination, and placebo.
- Assessment of blood pressure, PFWD, TWD, and WI.
Main Results:
- Captopril significantly reduced blood pressure and improved walking parameters (PFWD, TWD, WI).
- Ticlopidine showed a modest improvement in walking parameters but did not affect blood pressure.
- Combination therapy (C plus T) demonstrated the most significant improvements.
- Placebo led to a trend towards baseline values.
- Chronic administration over 12 months further enhanced all measured parameters.
Conclusions:
- Combined Captopril and Ticlopidine therapy is beneficial for hypertensive patients with intermittent claudication.
- The treatment significantly improves peripheral walking distance and time.
- Long-term combination therapy offers sustained benefits.
Abstract:
Twenty four male hypertensive patients suffering also from peripheral obstructive arterial disease were randomly subdivided in two groups and after a period of farmacological wash-out of one month Group I was treated with Captopril (C 50 mg bid) or Ticlopidine (T 250 mg bid) for three months and then with the association C plus T for three months again. After placebo administration for one month, patients were further treated with C plus T at low doses (25 mg bid and respectively 250 mg daily). In the first part of the study, patients of Group II received an inverse sequence of the drugs (before Ticlopidine 250 mg bid and then Captopril 50 bid). In both groups of patients C induced a significant decrease of blood pressure and an increase of PFWD, TWD, and WI. T did not modify blood pressure but slightly increased PFWD, TWD, and WI. The improvement was more evident during administration of C plus T, whereas placebo administration induced a trend toward baseline values. Finally, the chronic administration of C plus T for twelve months induced a further improvement of all considered parameters. In conclusion, chronic administration of C plus T may be useful in the treatment of hypertensive patients suffering from intermittent claudication, improving significantly PFWD and TWD.